Donate

News & Statements

Note from the Founder: World Diabetes Day 2017

Note from the Founder: World Diabetes Day 2017

I want people to understand that type 1 diabetes is not just something that people manage by simply taking some medicine and getting on their way. For many, it invades every part of our life, every day, and sometimes every minute. It sucks joy and causes unhinging worry. Read more

T1International calls for Financial Fairness for Canadians with Type 1 Diabetes

We call upon the Government of Canada to clarify whether or not type 1 diabetes qualifies for the Disability Tax Credit program, and for the government to remove all unnecessary barriers to insulin and supply access for people with diabetes. We support calls for the creation of a national universal pharmacare program, a frequently stated priority of the Canadian government, and note such a program would render this entire debate moot. Read more

Indianapolis #insulin4all Demonstration: Stop Price Gouging People with Diabetes!

Indianapolis #insulin4all Demonstration: Stop Price Gouging People with Diabetes!

Patients and those who support us will be demonstrating outside of Eli Lilly HQ in Indianapolis on Saturday, September 9th 2017. See the full post for more information and join us at https://www.facebook.com/groups/insulin4allAction/ if you can be there.
Read more

Recruiting for USA Insulin Access Study

In the wake of rising insulin prices in the United States and recent threats to public health safety nets like Medicaid, patients with type 1 diabetes are becoming increasingly more vulnerable. As a member of the T1D community and a rising second year Masters student at the Yale School of Public Health, Samantha Willner is hoping to shed light on the terrible sacrifices members of the T1D community in the U.S. have had to make in order to get the medicine they need to live. Read more

Organisations Unite in Open Letter to WHO Director-General-elect

Sixteen organisations have signed an open letter to Dr. Tedros Adhanom Ghebreyesus, the incoming Director-General of the World Health Organization. The letter, penned by T1International, praises his attention to diabetes and requests that more focus is put on access to insulin and treatment for everyone living with diabetes around the world. Read more

T1International Advocacy in Uganda

T1International Advocacy in Uganda

Recently, I was lucky enough to attend Camp Waromo, a four-day diabetes camp hosted by the Sonia Nabeta Foundation (SNF), a wonderful organisation working to ensure that everyone with diabetes in Africa has access to medicine and support they need. T1International was honoured to be invited and to share our advocacy resources and knowledge. Read more

An update on Insulin for Syrians

An update on Insulin for Syrians

Many of you supported T1International’s Insulin for Syrians campaign last year, when we raised funds for our partner organisation, the Syrian American Medical Society (SAMS) to ensure that people living with diabetes amidst the crisis in Syria would be able to have access to insulin and basic supplies. Read this update about the situation now and how your donation helped. Read more

Patients vs. Pharma: Hagens Berman files complaint against 'Big Three' insulin producers

Patients vs. Pharma: Hagens Berman files complaint against 'Big Three' insulin producers

The law firm Hagens Berman has filed a complaint against Eli Lilly, Novo Nordisk, and Sanofi, the ‘big three’ pharmaceutical companies that hold a near-monopoly on the insulin market. People living with type 1 diabetes will be the plaintiffs in this class action lawsuit, which alleges that Eli Lilly, Novo Nordisk and Sanofi have unjustly inflated their prices. Read more

T1International Year in Review: 2016

T1International Year in Review: 2016

What did T1International achieve in 2016? Lots! We raised funds to get insulin to Syrians in need, we carried out our Insulin & Supply survey to show how unaffordable type 1 diabetes really is, we launched the Type 1 Access Charter as well as the Advocacy toolkit, and so much more! Read more

Eli Lilly and Novo Nordisk: More Empty Promises

Eli Lilly and Novo Nordisk: More Empty Promises

Outrage at soaring insulin prices in the USA has been increasing. More patients and families are speaking out against unaffordable costs for life-saving medication than ever before. In response, two of the 'Big Three' insulin makers (who control over 90% of the insulin market) have recently made moves to combat this anger. Read more